Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Other selected financial assets
Total selected financial assets		$ 24,613	$ 38,157
Short-term borrowings:
Total short-term borrowings, carried at historical proceeds, as adjusted	[1]	13,633	10,159
Long-term debt:
Total long-term debt, carried at historical proceeds, as adjusted	[1]	30,437	28,740
Total		44,071	38,899
Total selected financial liabilities		45,926	40,608
Reported Value Measurement [Member]
Other selected financial assets
Held-to-maturity debt securities, carried at amortized cost	[2],[3]	1,270	1,388
Private equity securities, carried at equity-method or at cost	[3],[4]	1,003	1,336
Total		2,272	2,724
Long-term debt [Member]
Short-term borrowings:
Net fair value adjustments related to hedging and purchase accounting		2,447	1,294
Net unamortized discounts, premiums and debt issuance costs	[5]	(83)	(127)
Long-term debt:
Principal amount		28,073	27,573
Total long-term debt, carried at historical proceeds, as adjusted	[6]	30,437	28,740
Short-term Debt [Member]
Short-term borrowings:
Principal amount		13,602	10,160
Net fair value adjustments related to hedging and purchase accounting		47	2
Net unamortized discounts, premiums and debt issuance costs	[5]	(16)	(3)
Total short-term borrowings, carried at historical proceeds, as adjusted	[3]	13,633	10,159
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure [Abstract]
Trading funds and securities	[7],[8]	304	287
Selected financial assets measured at fair value on a recurring basis	[8],[9]	22,340	35,433
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	1,855	1,709
Fair Value, Measurements, Recurring [Member] | Interest Rate Swaps [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[8],[9]	1,923	837
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	3	139
Fair Value, Measurements, Recurring [Member] | Foreign Currency Swap [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[8],[9]	90	135
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	1,349	1,489
Fair Value, Measurements, Recurring [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[8],[9]	186	559
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	503	81
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[2],[8]	17,522	32,078
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[8]	1,724	934
Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[2],[8]	$ 590	$ 603

[1] Amounts may not add due to rounding.

[2] Gross unrealized gains and losses are not significant.

[3] The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 2, 2016 or December 31, 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments.

[4] Our private equity securities represent investments in the life sciences sector.

[5] We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information.

[6] The fair value of our long-term debt (not including the current portion of long-term debt) was $34.3 billion as of October 2, 2016 and $32.7 billion as of December 31, 2015. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the condensed consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.

[7] As of October 2, 2016, trading funds and securities are composed of $196 million of trading equity funds, $12 million of trading securities and $96 million of trading debt funds. As of December 31, 2015, trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of October 2, 2016 and December 31, 2015, trading equity funds of $69 million and $85 million, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.

[8] We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1C. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value.

[9] Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $91 million as of October 2, 2016; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015.

[10] Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $211 million and foreign currency forward-exchange contracts with fair values of $145 million as of October 2, 2016; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015.